Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal ACWY conjugate vaccine (Shaanxi Provincial Center for Disease Control and Prevention)
- Development stage
- Approved
- Lead developer
- Shaanxi Provincial Center for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal ACWY conjugate vaccine is a quadrivalent vaccine designed to prevent invasive meningococcal disease (IMD) caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. This specific candidate, developed by the Shaanxi Provincial Center for Disease Control and Prevention, consists of capsular polysaccharide antigens from these four serogroups, each conjugated to a carrier protein. Conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which enhances immunogenicity, induces higher antibody titers, and promotes immunological memory, particularly in infants and young children. The vaccine is currently in Phase III clinical trials in China to evaluate its safety and immunogenicity in healthy individuals aged 2 to 55 years.
- Brand names
- MenveoNimenrixMenactra
- Other names
- ACYW135 meningococcal polysaccharide conjugate vaccineACYW-135 meningococcal polysaccharide conjugate vaccineACYW 135 meningococcal polysaccharide conjugate vaccineMenACWY conjugate vaccineGroups ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal ACWY conjugate vaccine (Shaanxi Provincial Center for Disease Control and Prevention).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal ACWY conjugate vaccine (Shaanxi Provincial Center for Disease Control and Prevention).